Advertisement
Research Article

Predictive Markers of Efficacy for an Angiopoietin-2 Targeting Therapeutic in Xenograft Models

  • Gallen Triana-Baltzer,

    Affiliation: CovX Research, Pfizer Worldwide Research and Development, San Diego, California, United States of America

    X
  • Adam Pavlicek,

    Affiliation: Oncology Research Unit, Pfizer Worldwide Research and Development, San Diego, California, United States of America

    Current address: Regulus Therapeutics, San Diego, California, United States of America

    X
  • Ariadne Goulart,

    Affiliation: CovX Research, Pfizer Worldwide Research and Development, San Diego, California, United States of America

    Current address: Isis Therapeutics, Carlsbad, California, United States of America

    X
  • Hanhua Huang,

    Affiliation: CovX Research, Pfizer Worldwide Research and Development, San Diego, California, United States of America

    X
  • Steven Pirie-Shepherd mail,

    Steven.Pirie-Shepherd@pfizer.com

    Affiliation: Oncology Research Unit, Pfizer Worldwide Research and Development, San Diego, California, United States of America

    X
  • Nancy Levin

    Affiliation: CovX Research, Pfizer Worldwide Research and Development, San Diego, California, United States of America

    X
  • Published: November 14, 2013
  • DOI: 10.1371/journal.pone.0080132

About the Authors

Gallen Triana-Baltzer, Ariadne Goulart, Hanhua Huang, Nancy Levin
CovX Research, Pfizer Worldwide Research and Development, San Diego, California, United States of America
Adam Pavlicek, Steven Pirie-Shepherd
Oncology Research Unit, Pfizer Worldwide Research and Development, San Diego, California, United States of America

Corresponding Author

Email: Steven.Pirie-Shepherd@pfizer.com

Competing Interests

The authors of this manuscript declare their affiliation past or present with the commercial funder of this research Pfizer, Inc. All authors were employees of Pfizer at the time of this work and played roles in study design, data collection and analysis, decision to publish, and preparation of the manuscript. S. Pirie-Shepherd is a current employee of Pfizer, Inc. This does not alter the author's adherence to all the PLOS ONE policies on sharing data and materials. G. Triana-Baltzer, A. Goulart, H. Huang, and N. Levin are employees of CovX Research, Pfizer Worldwide Research Development. S. Pirie-Shephed is an employee of Oncology Research Unit, Pfizer Worldwide Research Development. A. Pavlicek is a former employee of Oncology Research Unit, Pfizer Worldwide Research and Development. The Angiopoietin-2 targeting compound described here, CVX-060, is being developed by Pfizer Inc. The authors of this manuscript were or are employees of Pfizer. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.

Author Contributions

Conceived and designed the experiments: GTB SPS NL HH. Performed the experiments: AG GTB. Analyzed the data: AP. Contributed reagents/materials/analysis tools: AP. Wrote the manuscript: GTB.